Latest news with #Paxlovid
Yahoo
2 hours ago
- Business
- Yahoo
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Super-high-yield stocks often deliver heaps of passive income early on, but they aren't famous for rapid payout raises. Pfizer offers a sky-high yield, but its payout has been rising slowly. Prologis offers a decent yield, and it's been raising its payout at an exciting pace. 10 stocks we like better than Prologis › Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows? Lately, Pfizer (NYSE: PFE) and Prologis (NYSE: PLD) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace. Here's a closer look at both to help you decide which one fits your goals. Shares of Pfizer have fallen about 62% from their COVID-19 pandemic highs. The stock is way down, but the company has raised its payout every year since 2009. At its beaten-down price, this stock offers an eye-popping 7.3% dividend yield. Pfizer's COVID-19 vaccine, Comirnaty, and antiviral treatment, Paxlovid, drove adjusted earnings up to $6.58 per share in 2022. Sinking demand for COVID-19 vaccines and treatments reduced adjusted earnings to just $3.11 per share last year. In 2025, Pfizer expects a significant earnings contraction. At the midpoint of the guided range management provided this April, adjusted earnings are expected to fall by 6.8% this year. The $2.80 per share management expects at the low end of the guided range is more than enough to support a dividend payout currently set at an annualized $1.72 annually, but there could be further contractions ahead. Eliquis is a next-generation blood thinner that Pfizer markets in collaboration with Bristol Myers Squibb. It's currently responsible for 14% of Pfizer's total revenue and is likely to lose ground to generic competition in the lucrative U.S. market in 2028. Long before Eliquis loses ground to generic competition, the company's lead growth driver, Vyndaquel, could stumble. BridgeBio launched a competing treatment called Attruby in late 2024, and it's been exceeding expectations. Pfizer's facing patent cliffs, but it also has one of the most productive development pipelines in the industry. Last year alone, the Food and Drug Administration issued more than a dozen approvals to new Pfizer treatments and several that are already on the market. With plenty of new products to market, the drugmaker has a good chance to continue its payout-raising streak in the decade ahead. As more folks do their shopping online, demand for warehouses that can support e-commerce has soared. By anticipating the demand, Prologis has become the world's largest real estate investment trust (REIT) that everyday investors can buy shares of. Fear and uncertainty regarding the taxes businesses need to pay when importing goods to the U.S. have pressured the stock. It's down about 12% from a peak it set in March. At its beaten-down price, it offers a 3.7% yield. Prologis has been able to raise its dividend by 11.7% annually over the past five years. At this pace, investors who buy at recent prices could begin receiving a double-digit yield on cost in less than a decade. Amazon, Home Depot, and FedEx are Prologis' largest customers. These three tenants are responsible for only 8.2% of the rent payments Proligis receives every month. This high level of diversification is a big reason it can boast industry-leading credit ratings. With an A2 rating from Moody's and an A rating from S&P Global, the weighted average interest rate on Prologis' outstanding debts was just 3.1% at the end of March. Acquiring and developing properties is an important part of this REIT's business, but it also acts as a lender. With an enviable credit rating, it can produce a strong profit while offering rates that its smaller competitors can't match. For companies that own their warehouses, selling them to Prologis and leasing them back is often their lowest-cost source of capital. With the vast majority of the world's logistics real estate still owned by the companies that use it, Prologis could continue growing at a rapid pace for decades to come. Pfizer offers a yield that's almost twice as high as Prologis's, but the pharmaceutical giant has been raising its payout at less than half the pace of the logistics REIT. Pfizer might be a good option for folks near retirement age. For income-seeking investors, though, Prologis seems like the better dividend stock to buy now. Before you buy stock in Prologis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Cory Renauer has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Bristol Myers Squibb, FedEx, Home Depot, Moody's, Pfizer, Prologis, and S&P Global. The Motley Fool recommends BridgeBio Pharma and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
2 days ago
- Health
- Time of India
Rapidly spreading COVID variant triggers fresh warnings — these are the symptoms doctors urge you to track
A new COVID variant called NB.1.8.1 is spreading fast in the world. It was first found in China in January 2025. Now, it makes up 10% of all COVID samples globally, which is a big jump from 2.5% four weeks ago, as per reports. The CDC said they're in touch with other countries about this variant. So far, only 20 cases have been found in the US, so it's not on the CDC COVID tracker yet. Doctors say this new variant causes similar symptoms to the older ones. The main signs are a dry cough that stays for long, blocked or runny nose, and feeling very tired. You may also get fever, chills, sore throat, and pain in your body. Most people can still do their normal things, but they'll feel more tired than usual, as per HuffPost report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Loja de Penápolis faz promoção de azeites Azeites Saiba Mais Undo There's no proof that NB.1.8.1 causes worse sickness or more people going to the hospital or dying. It has some new mutations on the spike protein that may help it spread faster and avoid the immune system. That means your body might not stop the virus as well as before, as per WHO. Scientists think the vaccines will still protect you from serious illness. NB.1.8.1 comes from the Omicron JN.1 family, which the 2024-2025 vaccines are made to fight. Vaccines might not fully stop infection, but they still help prevent serious problems. Live Events If you're older, have health problems, or take immune-lowering medicines, you should get vaccinated if it's been over 6 months since your last dose. If you're young and healthy, you probably don't need another shot right now, as per the HuffPost report. Most people can get better by just resting at home and drinking lots of fluids. If you have fever or body pain, you can take acetaminophen or ibuprofen. Normally, you'll feel better in about a week. If you are older or have a weak immune system, talk to a doctor. Doctors may give you antiviral pills like Paxlovid or Molnupiravir. These medicines work best within 5 days after symptoms start. Go to the hospital if you have chest pain, can't wake up or stay awake, feel confused or dizzy. The biggest red flag is trouble breathing , get help immediately if this happens, as per the HuffPost report. FAQs Q1. Do I need the vaccine for this new variant? Yes, if you are old, sick, or got your last shot over 6 months ago. Q2. Is there a new COVID virus? Yes, the new COVID variant is called NB.1.8.1.
Yahoo
4 days ago
- Business
- Yahoo
Terrible News for Pfizer Stock Investors
While it no longer generates the sales it once did, Pfizer's coronavirus lineup remains critical to its results. However, recent regulatory changes in the U.S. should make this franchise somewhat less lucrative. Even so, Pfizer's hopes of a comeback lie elsewhere, especially in its improving oncology unit. 10 stocks we like better than Pfizer › The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, they have been insufficient. And recent regulatory developments in the U.S. somewhat complicate things for the drugmaker. Here's what investors need to know. Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from Comirnaty, its COVID-19 vaccine, and Paxlovid, its therapy for the disease, started dropping off a cliff. However, Pfizer's coronavirus franchise has remained critical to its overall financial results. In 2024, the company's combined revenue from Paxlovid and Comirnaty was $11.1 billion. Pfizer's total top line came in at $63.6 billion, increasing 7% compared to the year-ago period. When excluding contributions from its coronavirus products, Pfizer's revenue grew more quickly -- by 12% year over year. The company's sales were down compared to 2023 but still accounted for about 17.5% of its top line. That's a meaningful amount. Pfizer would be in a lot more trouble without Paxlovid and Comirnaty. Here's the problem: Recent regulatory changes in the U.S. will make it more challenging for Pfizer to consistently generate solid revenue from Comirnaty. The U.S. Food and Drug Administration (FDA) has decided that instead of recommending COVID-19 vaccines for healthy adults and children above a certain age, it will do so only for seniors aged 65 and older and those with certain medical conditions that put them at risk of severe disease outcomes. The agency is requiring additional clinical trials before it can recommend annual booster shots for healthy adults. Healthy children and pregnant women are also no longer on the list of those who should take the vaccine. These changes will take effect in the fall, peak vaccination season for COVID-19. In other words, the U.S. coronavirus vaccine market just became smaller. What does this mean for investors? Pfizer's coronavirus franchise might weaken somewhat as a result of these changes, but perhaps not significantly. The FDA's guidance is largely irrelevant to Paxlovid. We could even speculate that lower vaccination rates may actually lead to higher infection rates and more prescriptions for the medicine. Although Comirnaty's U.S. sales will be affected, the company reported just $2.004 billion in revenue from the U.S. coronavirus vaccine market last year, which accounts for about 37% of the total revenue Comirnaty generated. The U.S. market is the single most important for Pfizer. Overall, these new developments won't have a significant impact on its financial results. Even so, Pfizer continues to encounter headwinds, and this is yet another one. It might not be a big deal in a vacuum, but given Pfizer's trajectory since 2022, it's not exactly what investors want to see. Truth be told: Pfizer needs every single dollar it can collect in sales. Even slightly lower revenue than it expects from any medicine or vaccine is terrible news for a company whose midpoint revenue guidance of $62.5 billion for the year implies a slight decrease compared to 2024. In light of all this, it's fair for investors to look at the company's performance over the past few years and wonder whether it can bounce back. If it does, it will unlikely be because of its work in the coronavirus vaccine market. Pfizer has made significant strides in recent years to strengthen its pipeline. One of its latest moves was to expand its already robust portfolio of oncology candidates with the licensing of a promising cancer medicine, called SSGJ-707, originally developed by China-based 3S Bio. Pfizer dished out an upfront payment of $1.25 billion for this mid-stage asset, with potential milestone payments of up to $4.8 billion on top of royalties. Pfizer's comeback story will almost certainly include at least one, if not several, significant regulatory wins in oncology. Given its massive pipeline in the field and vast experience in developing drugs in this area, the drugmaker should be well-positioned to achieve this goal. Pfizer is working on numerous therapies in other fields as well and is enhancing its business in various ways. The healthcare company has decreased expenses and costs and plans to continue doing so until 2027. In my view, thanks to its equally massive success in the coronavirus market earlier this decade, we have yet to see the results of the massive investments Pfizer made in its pipeline, It's not time to give up on the stock just yet, even with the recent regulatory changes in the U.S. Pfizer could still generate excellent returns for patient investors. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Terrible News for Pfizer Stock Investors was originally published by The Motley Fool Sign in to access your portfolio
Economic Times
24-05-2025
- Health
- Economic Times
COVID is back in a big way: Over 350 people are dying from the coronavirus in the U.S. each week, says CDC data
Despite available vaccines and treatments, COVID-19 continues to cause an average of 350 deaths weekly in the U.S., according to the CDC. Low vaccination rates, waning immunity, and delayed treatment contribute to these ongoing fatalities. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Are we using COVID treatments effectively? Tired of too many ads? Remove Ads Who is most at risk now? FAQs COVID is still around, and it is still deadly for a lot of Americans. The CDC says that the virus is killing multitudes in the U.S. each week, even though there are vaccines and treatments say that a lack of vaccinations and missed treatment opportunities are two of the main reasons why these deaths keep month, the Centers for Disease Control and Prevention (CDC) reported that COVID killed an average of 350 people every week, as per a report by CDC data indicates that although the number of deaths is high, it is declining and is less than the weekly deaths observed in prior spring months as well as the peak of 25,974 deaths recorded the week ending Jan. 9, health experts told ABC News that while the United States has made significant progress in recent years, high-risk groups are still at risk from COVID-19."The fact that we're still seeing deaths just means it's still circulating, and people are still catching it," Dr. Tony Moody, a professor at Duke University Medical Center's infectious diseases division's pediatric department, spoke to ABC News.A few factors, according to the experts, could be contributing to the virus's continued death toll, including low vaccination rates, declining immunity, and a lack of treatment to CDC data, as of the week ending April 26, only 23 percent of adults aged 18 and older received the updated COVID-19 vaccine during the 2024–25 to the data, only 13% of children received the updated COVID vaccine during the same time COVID deaths are likely a result of insufficient vaccination uptake, according to Dr. Gregory Poland, a vaccine specialist and president and co-director of the Atria Research Institute, which focuses on disease prevention. Some recipients of the vaccine, however, might not be exhibiting a healthy immune response."Some individuals might have a genetic predisposition to react poorly to the vaccine. Poland told ABC News, "The more common issue is that people are immunocompromised and can't respond well."Poland added that the chance of contracting COVID-19 increases as immunity to the vaccine wanes over is currently advised that people 65 and older get two doses of the updated COVID vaccine, spaced six months medications, such as Paxlovid from Pfizer and molnupiravir from Merck and Ridgeback Biotherapeutics, are currently available for COVID-19 are administered twice daily for five days and must be initiated within five days of the onset of COVID symptoms. Within seven days of the onset of COVID symptoms, the intravenous drug remdesivir must be elderly and those in high-risk groups are still very vulnerable. Many people don't use vaccines and antivirals correctly, which means the virus is still to CDC data, the highest rate of COVID-19 deaths is currently 4.66 per 100,000 in people 75 years of age and people are not receiving updated vaccines, and some are delaying treatment, allowing the virus to spread more adults, particularly those over 75, and people with weakened immune systems are still the most vulnerable.
Yahoo
24-05-2025
- Business
- Yahoo
Down 63%, Should You Buy the Dip on Pfizer?
Pfizer's woes range from a failed weight loss drug to tariffs and political uncertainty. Yet, Pfizer maintains a strong financial foundation and a promising pipeline. The stock's valuation is so low that even modest success could jumpstart the shares. 10 stocks we like better than Pfizer › It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago. But that's not all. Now, new challenges are putting pressure on the stock. Stocks aren't always on sale just because their prices went down, but Pfizer's storied history and 7.3% dividend yield make it worth checking under the hood to see if the company has what it takes to get back on track. So, that's precisely what this Fool did. Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) and an antiviral drug (Paxlovid) that made billions of dollars during COVID-19. Then, as those sales dried up, the company's top and bottom lines shrank, taking Pfizer's stock price down, too. But that's old news. More recently, Pfizer has endured a barrage of additional bad news. The company ceased development of Danuglipron, an experimental weight loss pill after it potentially caused a liver injury in a patient. That was supposed to be Pfizer's entrance into one of healthcare's fastest-growing markets. The political headaches are stacking up, too. New Secretary of Health and Human Services Robert F. Kennedy Jr. has been a vocal critic of the pharmaceutical industry and is no friend of Pfizer's. Earlier this month, President Trump issued an executive order to lower drug prices in the United States. Then, you have potential tariff policies that could make it harder for Pfizer to strategize how it develops and manufactures its drugs. Lastly, Pfizer is anticipating a $1 billion revenue hit in 2025 due to Medicare changes stemming from the Biden Administration's Inflation Reduction Act. Phew. It's a mouthful, but these problems seem more like paper cuts than fatal wounds. Danuglipron's failure hurts, but Pfizer still has a healthy pipeline that will heavily focus on oncology over the coming years. Then there is the political noise, which investors shouldn't rush to panic over. For example, President Trump's executive order on drug prices lacked a clear framework for what drugs might be susceptible to pricing pressure or how exactly the government would force drug companies to comply. Acknowledging risks is fair, but try not to overreact to them. Pfizer has a solid financial foundation. The company's credit is investment-grade, and its dividend payout ratio is only 61% of the bottom end of management's 2025 earnings guidance. Pfizer is also beginning a cost-savings program that it anticipates will save it $7.7 billion by the end of 2027. So, that juicy 7.3% dividend yield is likely not a warning sign of a looming cut. It seems the market may be assuming the worst. Pfizer trades at less than 8 times its 2025 earnings guidance, which practically values the stock like it's on death's door. For reference, the S&P 500's price-to-earnings ratio is 28. You can see below how the market's expectations for Pfizer's long-term growth have plunged since October: The great thing about setting a low bar is that it's easy to step over. With Pfizer's 7.3% dividend, investors only need low-single-digit earnings growth to generate 10% annualized investment returns. Barring Pfizer utterly imploding, that could be a lowball scenario. Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, Pfizer could be a market-beating stock. The S&P 500 averages 10% returns historically, and its high valuation could drag on the market's future performance. If Pfizer's growth winds up higher, near where analysts thought it could be last fall, then you might see the stock's valuation rise, which would only turbocharge returns. There are no guarantees, of course. That's why you diversify and own many stocks. That said, Pfizer stands out in a broader stock market that doesn't seem to have many potential home runs right now. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Down 63%, Should You Buy the Dip on Pfizer? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
